Trial intelligence / Profile preview

A-CHOP regimen in newly diagnosed angioimmunoblastic T-cell lymphoma

ChiCTR2100054900Phase 4Recruiting

Sponsor
First Affiliated Hospital, Zhejiang University School of Medicine
Start
Jan 2022
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of azacitidine in angioimmunoblastic T-cell lymphoma (AITL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete response rate. Started Jan 2022; status: recruiting.

02

Drugs

azacitidine
03

Conditions

angioimmunoblastic T-cell lymphoma (AITL)

Beyond the preview

Go deeper on ChiCTR2100054900.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100054900.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call